Literature DB >> 36268388

Role of Magnetic Resonance Imaging (MRI) in grading gliomas comparable with pathology: A cross-sectional study from Syria.

Nisreen Haydar1, Khatoun Alyousef2, Usama Alanan3, Rana Issa4, Fawaz Baddour1, Zuheir Al-Shehabi5, Moatasem Hussein Al-Janabi6.   

Abstract

Objective: Gliomas are one of the most common brain tumors in adults with a poor prognosis in most patients. Magnetic Resonance Imaging (MRI) plays a critical role in the diagnosis, management, and follow-up of gliomas. The aim of this study is to assess the sensitivity and specificity of MRI in the preoperative grading of supratentorial gliomas in comparison to histopathology.
Methods: A cross-sectional study included 39 patients, aged between 40 and 75 years with histologically diagnosed supratentorial gliomas who underwent conventional MR imaging, which included T1, T2, and FLAIR sequences from November 2018-December 2019 in the Department of Neurosurgery, Tishreen University Hospital, Lattakia. The histopathological typing and grading of the tumor were done by using 2016 WHO classification. The sensitivity, specificity, predictive value, and accuracy of MRI in determining tumor grade were calculated. The comparison was done between MRI findings and WHO histopathological grading.
Results: The overall sensitivity and specificity of MRI findings in the assessment of high-grade gliomas were 100% and 91% respectively. The positive predictive value (PPV) was 66.6%, and the negative predictive value (NPV) was 100%. The overall accuracy was 94.9%. The agreement between histopathological and MRI findings was 72%. Conclusions: MRI plays an essential role in the initial diagnosis and grading of supratentorial gliomas with high sensitivity and specificity. It is considered a non-invasive method and is useful in cases where the biopsy procedure is a contraindication or rejected by the patient.
© 2022 The Authors.

Entities:  

Keywords:  Glioblastoma; Gliomas; Histopathology; Magnetic resonance imaging

Year:  2022        PMID: 36268388      PMCID: PMC9577635          DOI: 10.1016/j.amsu.2022.104679

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  9 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

Review 2.  Conventional MRI evaluation of gliomas.

Authors:  N Upadhyay; A D Waldman
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 3.  Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Authors:  Alena Horská; Peter B Barker
Journal:  Neuroimaging Clin N Am       Date:  2010-08       Impact factor: 2.264

Review 4.  Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.

Authors:  Krishanthan Vigneswaran; Stewart Neill; Costas G Hadjipanayis
Journal:  Ann Transl Med       Date:  2015-05

Review 5.  Molecular diagnostics of gliomas.

Authors:  Marina N Nikiforova; Ronald L Hamilton
Journal:  Arch Pathol Lab Med       Date:  2011-05       Impact factor: 5.534

6.  STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.

Authors:  Ginimol Mathew; Riaz Agha
Journal:  Int J Surg       Date:  2021-11-11       Impact factor: 6.071

7.  Role of Diffusion and Perfusion Magnetic Resonance Imaging in Predicting the Histopathological Grade of Gliomas - A Prospective Study.

Authors:  Yawar Shoaib; Khursheed Nayil; Rumana Makhdoomi; Abraq Asma; Altaf Ramzan; Feroze Shaheen; Abrar Wani
Journal:  Asian J Neurosurg       Date:  2019 Jan-Mar

8.  Diagnostic accuracy of magnetic resonance imaging in detection of intra-axial gliomas.

Authors:  Sohbia Munir; Sohail Ahmed Khan; Hina Hanif; Maria Khan
Journal:  Pak J Med Sci       Date:  2021 Jan-Feb       Impact factor: 1.088

Review 9.  Advanced MR imaging of gliomas: an update.

Authors:  Hung-Wen Kao; Shih-Wei Chiang; Hsiao-Wen Chung; Fong Y Tsai; Cheng-Yu Chen
Journal:  Biomed Res Int       Date:  2013-06-04       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.